Tag: Low platelets

In a recent meta-analysis of multiple sclerosis (MS) patients treated with alemtuzumab, secondary immune thrombocytopenia (ITP) was noted to occur with a specific incidence rate. This highlights the nuanced answer to the question: *Do people with MS have low platelets?* The association is not direct but is often linked to medication side effects or the broader autoimmune nature of the disease.

Based on postmarketing reports, Tysabri (natalizumab) has been linked to cases of thrombocytopenia, a serious condition involving low platelet counts. So, does Tysabri cause low platelets? Yes, and it's a risk that patients and clinicians must be aware of to ensure proper management and timely intervention.

Drug-induced immune thrombocytopenia (DITP) affects an estimated 10 per million people annually [1.3.1]. This condition raises a critical question for many patients and clinicians: **what medications destroy platelets?** Understanding the drugs responsible is the first step in managing this serious adverse reaction.